Arylamidrazones as novel corticotropin releasing factor receptor antagonists.
J Med Chem
; 45(11): 2123-6, 2002 May 23.
Article
en En
| MEDLINE
| ID: mdl-12014949
ABSTRACT
The arylamidrazones have been found to be potent corticotropin releasing factor (CRF) receptor antagonists structurally distinct from previously reported CRF1 antagonists. Attempts to modify the arylamidrazone core suggested an important role for the anilino NH moiety. The right-hand-side 2-nitro feature in lead 1 could be replaced with substituents methyl, chloro, cyano, or trifluoromethyl with a 4- to 10-fold reduction in receptor binding. With appropriate left-hand-side modifications, this potency loss could be recovered.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Receptores de Hormona Liberadora de Corticotropina
/
Hidrazinas
/
Compuestos de Anilina
Límite:
Animals
Idioma:
En
Revista:
J Med Chem
Asunto de la revista:
QUIMICA
Año:
2002
Tipo del documento:
Article